http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106860460-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 |
| filingDate | 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106860460-B |
| titleOfInvention | Application of the glutaminase inhibitor C B-839 in the drug of preparation treatment estrogen sensitive type carcinoma of endometrium |
| abstract | The present invention relates to application of the glutaminase inhibitor C B-839 in the drug of preparation treatment estrogen sensitive type carcinoma of endometrium.The present invention is confirmed through experiment in vitro and internal animal experiment, CB-839 can effectively inhibit the enhancing of the carcinoma of endometrium glutamine metabolism level because caused by stimulating estrogen, and then inhibit the metabolism of endometrial carcinoma cell glutamine, conducive to the growth of limitation tumour, oral CB-839 can significantly reverse the carcinoma of endometrium glutamine metabolism increase because of estrogen level caused by abnormal.Therefore CB-839 can be used for preparing the drug for the treatment of estrogen sensitive type carcinoma of endometrium. |
| priorityDate | 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 223.